AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.2483
+0.0083 (3.46%)
At close: Oct 27, 2026, 4:00 PM EDT
0.2436
-0.0047 (-1.89%)
After-hours: Oct 27, 2026, 4:56 PM EDT
AEON Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
12.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.62M |
| Bolt Biotherapeutics | 4.70M |
| Cerenome | 4.20M |
| SeaStar Medical Holding | 1.71M |
| Lipocine | 1.57M |
| Daré Bioscience | 1.37M |
| Pluri | 1.02M |
| Vyome Holdings | 129.73K |
AEON News
- 1 day ago - AEON Biopharma Proxy statement: Proxy filing - Filings
- 5 days ago - AEON Biopharma Slides: Corporate presentation - Filings
- 14 days ago - AEON Biopharma Proxy statement: Proxy filing - Filings
- 26 days ago - Aeon Biopharma price target raised to $2 from $1 at Lake Street - TheFly
- 27 days ago - Aeon FDA Type 2b meeting feedback clarifies development plan for ABP-450 - TheFly
- 27 days ago - AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 - GlobeNewsWire
- 6 weeks ago - Aeon Biopharma announces results from ABP-450 pilot forced degradation study - TheFly
- 6 weeks ago - AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® - GlobeNewsWire